|
|
|
42
|
A531AH
|
LOUTEN EMULSION 0.005% EYE DR (LPO) LATA
|
LATANOPROST
|
LOUTEN EMULSION
|
2.5ML
|
C
|
16.31
|
16.31
|
BOTT
|
1
|
BOTT
|
LPO
|
LABORATORIOS POEN S.A.
|
COL
|
AVENTA BARBADOS
|
B
|
524028
|
EENT PROSTAGLANDIN ANALOGS
|
2026-04-01
|
2028-03-31
|
|
OPHTHALMIC
|
6
|
EENT PROSTAGLANDIN ANALOGS
|
|
|
|
|
41
|
A531AW
|
BIMATOPROST 0.01% EYE DR (CIR)
|
BIMATOPROST
|
BIMATOPROST
|
2.5ML
|
A
|
9.24
|
9.24
|
BOTT
|
1
|
BOTT
|
CIR
|
CIRON PHARMA
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
B
|
524028
|
EENT PROSTAGLANDIN ANALOGS
|
2024-07-23
|
2025-01-16
|
|
OPHTHALMIC
|
6
|
EENT PROSTAGLANDIN ANALOGS
|
2024-07-23
|
|
|
|
41
|
A531AW
|
BIMATOPROST 0.01% EYE DR (CIR)
|
BIMATOPROST
|
BIMATOPROST
|
2.5ML
|
A
|
12.83
|
12.83
|
BOTT
|
1
|
BOTT
|
CIR
|
CIRON PHARMA
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
B
|
524028
|
EENT PROSTAGLANDIN ANALOGS
|
2025-01-17
|
2026-03-31
|
|
OPHTHALMIC
|
6
|
EENT PROSTAGLANDIN ANALOGS
|
2025-01-17
|
|
|
|
40
|
A531AZ
|
TRAVATAN BAK 0.004% EYE DR (NVS/COL) TRAVOPROST
|
TRAVOPROST
|
TRAVATAN BAK
|
2.5ML
|
A
|
10.87
|
10.87
|
EYE DROP
|
1
|
BOTT
|
NVS
|
NOVARTIS CARIBE SA
|
COL
|
COLLINS LTD
|
B
|
524028
|
EENT PROSTAGLANDIN ANALOGS
|
2022-04-01
|
2024-03-31
|
|
OPHTHALMIC
|
6
|
EYE, EAR, NOSE AND THROAT PREPARATIONS
|
|
|
|
|
41
|
A531AZ
|
TRAVATAN BAK 0.004% EYE DR (NVS) TRAVOPROST
|
TRAVOPROST
|
TRAVATAN BAK
|
2.5ML
|
A
|
10.87
|
10.8733
|
BOTT
|
1
|
BOTT
|
NVS
|
NOVARTIS CARIBE SA
|
COL
|
COLLINS LTD
|
B
|
524028
|
EENT PROSTAGLANDIN ANALOGS
|
2024-04-01
|
2026-03-31
|
|
OPHTHALMIC
|
6
|
EENT PROSTAGLANDIN ANALOGS
|
|
|
|
|
42
|
A531AZ
|
TRAVATAN BAK 0.004% EYE DR (NVS) TRAVOPROST
|
TRAVOPROST
|
TRAVATAN BAK
|
2.5ML
|
A
|
10.82
|
10.82
|
BOTT
|
1
|
BOTT
|
NVS
|
NOVARTIS CARIBE SA
|
COL
|
AVENTA BARBADOS
|
B
|
524028
|
EENT PROSTAGLANDIN ANALOGS
|
2026-04-01
|
2028-03-31
|
|
OPHTHALMIC
|
6
|
EENT PROSTAGLANDIN ANALOGS
|
|
|
|
|
41
|
A531BF
|
XALATAN 0.005% EYE DR (PFI) LATANOPROST
|
LATANOPROST
|
XALATAN
|
2.5ML
|
A
|
8.86
|
8.8617
|
BOTT
|
2
|
BOTT
|
PFI
|
PFIZER CORPORATION
|
COL
|
COLLINS LIMITED
|
B
|
524028
|
EENT PROSTAGLANDIN ANALOGS
|
2024-04-01
|
2026-03-31
|
|
OPHTHALMIC
|
6
|
EENT PROSTAGLANDIN ANALOGS
|
2025-04-01
|
|
|
|
42
|
A531BF
|
XALATAN 0.005% EYE DR (PFI) LATANOPROST
|
LATANOPROST
|
XALATAN
|
2.5ML
|
A
|
8.51
|
8.51
|
BOTT
|
1
|
BOTT
|
PFI
|
PFIZER CORPORATION
|
COL
|
AVENTA BARBADOS
|
B
|
524028
|
EENT PROSTAGLANDIN ANALOGS
|
2026-04-01
|
2028-03-31
|
|
OPHTHALMIC
|
6
|
EENT PROSTAGLANDIN ANALOGS
|
|
|
|
|
42
|
A531BH
|
BITOD LS 0.01% EYE DR (SYP) BIMATOPROST
|
BIMATOPROST
|
BITOD LS
|
3ML
|
A
|
8.54
|
8.54
|
BOTT
|
1
|
BOTT
|
SYP
|
SYAASH PHARMACEUTICALS
|
PSB
|
PHARMACEUTICAL SOLUTIONS BARBA
|
B
|
524028
|
EENT PROSTAGLANDIN ANALOGS
|
2026-04-01
|
2028-03-31
|
|
OPHTHALMIC
|
6
|
EENT PROSTAGLANDIN ANALOGS
|
|
|
|
|
40
|
A531H
|
XALATAN 0.005% EYE DR (PFI/SBI) LATANOPROST
|
LATANOPROST
|
XALATAN
|
2.5ML
|
A
|
11.66
|
11.66
|
EYE DROP
|
1
|
BOTT
|
PFI
|
PFIZER CORPORATION
|
SBI
|
MASSY DISTRIBUTION (BDOS) LTD
|
B
|
524028
|
EENT PROSTAGLANDIN ANALOGS
|
2022-04-01
|
2024-03-31
|
Price Change
|
OPHTHALMIC
|
6
|
EYE, EAR, NOSE AND THROAT PREPARATIONS
|
2022-05-03
|
|
|
|
41
|
A531H
|
XALATAN 0.005% EYE DR (PFI) LATANOPROST
|
LATANOPROST
|
XALATAN
|
2.5ML
|
A
|
8.86
|
8.8617
|
BOTT
|
1
|
BOTT
|
PFI
|
PFIZER CORPORATION
|
SBI
|
MASSY DISTRIBUTION (BDOS) LTD
|
B
|
524028
|
EENT PROSTAGLANDIN ANALOGS
|
2024-04-01
|
2026-03-31
|
|
OPHTHALMIC
|
6
|
EENT PROSTAGLANDIN ANALOGS
|
|
|
|
|
40
|
A531J
|
LUMIGAN 0.01% EYE DR (ALL/COL) BIMATOPROST
|
BIMATOPROST
|
LUMIGAN
|
2.5ML
|
C
|
41.32
|
41.32
|
EYE DROP
|
0
|
BOTT
|
ALL
|
ALLERGAN INTERNATIONAL
|
COL
|
COLLINS LTD
|
B
|
524028
|
EENT PROSTAGLANDIN ANALOGS
|
2022-04-01
|
2024-03-31
|
|
OPHTHALMIC
|
0
|
EYE, EAR, NOSE AND THROAT PREPARATIONS
|
|
|
|
|
41
|
A531J
|
LUMIGAN 0.01% EYE DR (ALL) BIMATOPROST (C)
|
BIMATOPROST
|
LUMIGAN
|
2.5ML
|
C
|
41.32
|
41.3185
|
BOTT
|
1
|
BOTT
|
ALL
|
ALLERGAN INTERNATIONAL
|
COL
|
COLLINS LTD
|
B
|
524028
|
EENT PROSTAGLANDIN ANALOGS
|
2024-04-01
|
2026-03-31
|
|
OPHTHALMIC
|
6
|
EENT PROSTAGLANDIN ANALOGS
|
|
|
|
|
42
|
A531J
|
LUMIGAN 0.01% EYE DR (ALL) BIMATOPROST
|
BIMATOPROST
|
LUMIGAN
|
2.5ML
|
C
|
41.32
|
41.32
|
BOTT
|
1
|
BOTT
|
ALL
|
ALLERGAN INTERNATIONAL
|
COL
|
AVENTA BARBADOS
|
B
|
524028
|
EENT PROSTAGLANDIN ANALOGS
|
2026-04-01
|
2028-03-31
|
|
OPHTHALMIC
|
6
|
EENT PROSTAGLANDIN ANALOGS
|
|
|
|
|
40
|
A531W
|
SAFLUTAN 0.015MG/ML EYE DR (MSD/STO) TAFLUPROST
|
TAFLUPROST
|
SAFLUTAN
|
30X0.3ML
|
B
|
36.43
|
36.43
|
EYE DROP
|
0
|
AMP
|
MSD
|
MERCK SHARP & DOHME (I.A.) CORP
|
STO
|
BRYDEN STOKES LTD
|
|
524028
|
EENT PROSTAGLANDIN ANALOGS
|
2022-04-01
|
2024-03-31
|
|
OPHTHALMIC
|
6
|
EYE, EAR, NOSE AND THROAT PREPARATIONS
|
|
|
|
|
41
|
A573H
|
ALENDRONATE 70MG TAB (CIP) (B)
|
ALENDRONATE
|
ALENDRONATE
|
40'S
|
B
|
21.94
|
0.5484
|
TAB
|
5
|
BOX
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
9224
|
BONE RESORPTION INHIBITORS
|
2024-04-01
|
2026-03-31
|
|
ORAL
|
6
|
BONE RESORPTION INHIBITORS
|
|
|
|
|
42
|
A573K
|
ALENDRONATE 70MG TAB (CIP)
|
ALENDRONATE
|
ALENDRONATE
|
4'S
|
BQ
|
3.78
|
0.95
|
TAB
|
5
|
BLIS
|
CIP
|
CIPLA LTD
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
9224
|
BONE RESORPTION INHIBITORS
|
2026-04-01
|
2028-03-31
|
|
ORAL
|
0
|
BONE RESORPTION INHIBITORS
|
|
|
|
|
40
|
A573P
|
ALENDRONATE 70MG TAB (APL/AHI)
|
ALENDRONATE
|
ALENDRONATE
|
4'S
|
B
|
3.62
|
0.91
|
TABLET
|
0
|
TAB
|
APL
|
AUROBINDO PHARMA LTD.
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
9224
|
BONE RESORPTION INHIBITORS
|
2022-04-01
|
2024-03-31
|
|
Oral
|
6
|
UNCLASSIFIED THERAPEUTIC AGENTS
|
|
|
|
|
40
|
A5916
|
DOXORUBICIN 50MG SOLN FOR INJ (EBA/COL)
|
DOXORUBICIN
|
DOXORUBICIN
|
50MG VIAL
|
BQ
|
34.93
|
34.93
|
SOLUTION FOR
|
0
|
VIAL
|
EBA
|
EBEW ARZNEIMITTLE GES.MBH
|
COL
|
COLLINS LTD
|
|
1000
|
ANTINEOPLASTICS
|
2022-04-01
|
2024-03-31
|
Price Change
|
IV
|
0
|
ANTINEOPLASTICS
|
2022-01-18
|
|
|
|
40
|
A591AA
|
DOXORUBICIN 50MG SOLN FOR INJ (DIL/AHI)
|
DOXORUBICIN
|
DOXORUBICIN
|
50MG VIAL
|
BQ
|
25.91
|
25.91
|
SOLUTION FOR
|
0
|
VIAL
|
DIL
|
FRESENIUS KABI
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
1000
|
ANTINEOPLASTICS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
ANTINEOPLASTICS
|
|